For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Takeda’s Novel Diabetes Treatment GPR40 Shows Efficacy in Japanese Patients in PIII Trial
May 20, 2013
- New Rules on Settai Resulted in Fewer Serious Violations of Fair Competition Code in FY2012: Industry FTC
May 20, 2013
- 3 Major Generic-Only Makers Offer Mixed Views on Govt Promotion Measures
May 17, 2013
- FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
- Toyama Chemical to License Novel Macrolide Agent from Cempra
May 17, 2013
- Yakult to File Elplat for New Indications of Pancreas and Gastric Cancer
May 17, 2013
- Astellas to File NDA for Enzalutamide in Japan in 1st Half of FY2013
May 17, 2013
- FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
- Astellas to Reorganize Research Functions, Shut Down US Subsidiaries
May 16, 2013
- Pres. Sagara Says Profit Increase Still Ways Away, Company to Invest to Enhance Pipeline: Ono
May 16, 2013
- PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu
May 16, 2013
- Investigation on Ranbaxy Quality Issue Ends, Risks Eliminated: Daiichi Sankyo Pres.
May 15, 2013
- Eisai Forecasts 1st Sales Rise in 4 Years in FY2013, Business Slump to Bottom Out: Pres. Naito
May 15, 2013
- Otsuka Holdings’ Pharma Sales Up 8.8% in FY2012, Spurred by Upbeat Abilify
May 15, 2013
- Diabetes Treatment Market to Exceed 500 Billion Yen in 2017: Fuji-Keizai
May 15, 2013
- Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
- Astellas’s FY2012 Sales Top 1 Trillion Yen; XTANDI Scores 12.2 Billion Yen in 1st Year
May 14, 2013
- Ono Sales Down 0.3% Despite New Product Sales Increase, Double-Digit Decline in Profits Due to Higher Cost to Sales Ratio
May 14, 2013
- Takeda Not to Release 3-Year Mid-Term Business Plan, Changes to Annual Business Forecast
May 14, 2013
- Eisai Operating Profit Down 26%, Fails to Meet Revised Domestic Sales Target for Aricpet
May 14, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…